Literature DB >> 18661522

Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway.

Richard M Martin1, Lars Vatten, David Gunnell, Pål Romundstad, Tom I L Nilsen.   

Abstract

Screening for early prostate cancer is frequently employed in the routine management of men with lower urinary tract symptoms (LUTS), but the evidence-base linking LUTS with prostate cancer is limited. We assessed the association of LUTS with a subsequent prostate cancer diagnosis in a prospective cohort study based on 21,159 Norwegian men who completed baseline questionnaires, including the International Prostate Symptom Score (IPSS) questionnaire, between 1995 and 2007 as part of the second Nord-Trøndelag Health Study (HUNT 2). Men were followed-up for prostate cancer incidence and mortality from the date of clinical examination to end 2005. During a mean of 9 years follow-up, 518 incident prostate cancers were diagnosed and 74 men died from prostate cancer. Men with severe LUTS (IPSS 20-35) had a 2.26-fold (95% CI: 1.49-3.42) increased risk of prostate cancer compared to men reporting no symptoms. A positive association was observed for localized (hazard ratio, HR: 4.61; 2.23-9.54), but not advanced (HR: 0.51; 0.15-1.75), cancers (p for heterogeneity <0.001). There was no evidence that moderate/severe symptoms (IPSS 8-35) were associated with prostate cancer mortality (HR: 0.83; 0.42-1.64) vs. no symptoms. Amongst 518 men with prostate cancer, there was a 46% lower (10-68%) risk of death with moderate/severe symptoms vs. no symptoms. We conclude that LUTS are positively associated with localized, but not advanced or fatal, prostate cancer, suggesting that urinary symptoms are not caused by prostate cancer. Thus, screening for early cancers on the basis of LUTS may not be justified.

Entities:  

Mesh:

Year:  2008        PMID: 18661522     DOI: 10.1002/ijc.23713

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.

Authors:  Maria Frånlund; Sigrid Carlsson; Johan Stranne; Gunnar Aus; Jonas Hugosson
Journal:  BJU Int       Date:  2012-04-30       Impact factor: 5.588

Review 2.  Epidemiology and treatment modalities for the management of benign prostatic hyperplasia.

Authors:  Soum D Lokeshwar; Benjamin T Harper; Eric Webb; Andre Jordan; Thomas A Dykes; Durwood E Neal; Martha K Terris; Zachary Klaassen
Journal:  Transl Androl Urol       Date:  2019-10

3.  Baseline patient reported outcomes data shows high prevalence of overactive bladder, sexual dysfunction, depression and anxiety in Canadian men with newly diagnosed localized prostate cancer.

Authors:  Henry Han-I Yao; Robert Trafford Crump; Camille Charbonneau; Asher Khan; Carly Barton; Hilary Brotherhood; Jing Jiang; Kevin V Carlson; Richard J Baverstock
Journal:  Transl Androl Urol       Date:  2020-10

Review 4.  Defining the threshold for significant versus insignificant prostate cancer.

Authors:  Theo H Van der Kwast; Monique J Roobol
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

5.  Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.

Authors:  Grace J Young; Sean Harrison; Emma L Turner; Eleanor I Walsh; Steven E Oliver; Yoav Ben-Shlomo; Simon Evans; J Athene Lane; David E Neal; Freddie C Hamdy; Jenny L Donovan; Richard M Martin; Chris Metcalfe
Journal:  BMJ Open       Date:  2017-10-30       Impact factor: 2.692

Review 6.  Prostate Cancer in Primary Care.

Authors:  Samuel W D Merriel; Garth Funston; Willie Hamilton
Journal:  Adv Ther       Date:  2018-08-10       Impact factor: 3.845

7.  Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study.

Authors:  Visalini Nair-Shalliker; Albert Bang; Sam Egger; Xue Qin Yu; Karen Chiam; Julia Steinberg; Manish I Patel; Emily Banks; Dianne L O'Connell; Bruce K Armstrong; David P Smith
Journal:  Br J Cancer       Date:  2022-05-24       Impact factor: 9.075

8.  Patient delay in cancer studies: a discussion of methods and measures.

Authors:  Rikke Sand Andersen; Peter Vedsted; Frede Olesen; Flemming Bro; Jens Søndergaard
Journal:  BMC Health Serv Res       Date:  2009-10-19       Impact factor: 2.655

9.  Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate Biopsy.

Authors:  Luigi Cormio; Giuseppe Lucarelli; Oscar Selvaggio; Giuseppe Di Fino; Vito Mancini; Paolo Massenio; Francesco Troiano; Francesca Sanguedolce; Pantaleo Bufo; Giuseppe Carrieri
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

10.  Lower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise?

Authors:  Jasmine Just; Fiona Osgun; Claire Knight
Journal:  Br J Gen Pract       Date:  2018-11       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.